A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
Open Access
- 1 October 2000
- journal article
- clinical trial
- Published by Wiley in Arthritis & Rheumatism
- Vol. 43 (10) , 2316-2327
- https://doi.org/10.1002/1529-0131(200010)43:10<2316::aid-anr20>3.0.co;2-6
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Factors predicting response to treatment in rheumatoid arthritis: The importance of disease durationArthritis & Rheumatism, 2000
- A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving MethotrexateNew England Journal of Medicine, 1999
- Treatment of Rheumatoid Arthritis with Methotrexate Alone, Sulfasalazine and Hydroxychloroquine, or a Combination of All Three MedicationsNew England Journal of Medicine, 1996
- Guidelines for monitoring drug therapy in rheumatoid arthritisArthritis & Rheumatism, 1996
- Special article the economic cost and social and psychological impact of musculoskeletal conditionsArthritis & Rheumatism, 1995
- Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid ArthritisNew England Journal of Medicine, 1995
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- The total costs of drug therapy for rheumatoid arthritisArthritis & Rheumatism, 1995
- Efficacy of Low-Dose Methotrexate in Rheumatoid ArthritisNew England Journal of Medicine, 1985
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980